Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

t is being prepared.

?These three Phase II clinical trials sponsored by NCI are components of a clinical trials program designed to identify signals of clinical activity of ispinesib across multiple tumor types,? stated Dr. Andrew A. Wolff, Cytokinetics Senior Vice President of Clinical Research and Development and Chief Medical Officer. ?Although these three trials did not meet the protocol-specified criteria for progression, we are encouraged by the anti-cancer activity of ispinesib observed to date in three other Phase II trials in breast, ovarian and non-small cell lung cancers. Based on these data, we plan to move forward in further clinical development of ispinesib with a focused approach to the potential treatment of breast cancer with ispinesib.?

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the NCI. GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these trials has been closed. To date, clinical activity with ispinesib has been observed in breast cancer, in non-small cell lung cancer, and ovarian cancer with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. In this clinical trial, The best overall responses observed with ispinesib were partial responses in 4 of 45 evaluable patients as measured by the RECIST criteria. Responses were confirmed by independent radiology review and were seen in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/2/2015)... 2015 Releases of the genetically ... aegypti , , reduced the dengue mosquito population ... by 95%, well below the modelled threshold for ... The journal PLOS Neglected Tropical Diseases published ... engineered mosquitoes. The results showed that in Juazeiro city, ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/n7kzjb/vitamin_d_market ) has ... Analog, Application, End-User & by Region - Global Trends & ... This market is projected to reach about $2.5 Million by ... and rising opportunities in countries such as India ... , and Brazil . In 2013, ...
(Date:7/2/2015)... -- The Green Exchange, Inc., the developer,s of "Loud Cannabis" ... app that connects cannabis growers directly to patients to ... that their service provides the fastest delivery on the ... half a dozen other delivery apps that have popped ... in that it connects growers directly with patients. ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
... 2011 Stereotaxis, Inc. (NASDAQ: STXS ) today ... conferences during May 2011: The Deutsche Bank ... and Chief Executive Officer of Stereotaxis, is scheduled to present ... at 4:10 p.m. ET. The JMP Securities Annual Research ...
... Pharmasset, Inc. (Nasdaq: VRUS ), a clinical ... novel drugs to treat viral infections, today reported financial ... 31, 2011. Financial ResultsRevenues were ... compared to $0.3 million for the quarter ended March ...
Cached Medicine Technology:Stereotaxis to Present at Upcoming Investor Conferences 2Stereotaxis to Present at Upcoming Investor Conferences 3Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 5
(Date:7/3/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national chief nursing officer recruitment for Jane Phillips Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national ... Powder Cancer Lawsuit Center website. Just as the previous version did, the new website ... timely lawsuit updates and ovarian cancer warning information. The site is routinely updated with ...
(Date:7/3/2015)... ... ... Selfie on a Stick ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... smartphone has an incredibly powerful camera built into it. And when someone is traveling ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently ... similar to those of celebrities will have the opportunity to get 10% discount on ... ensures that people do not have to use coupon codes or remember redemption codes. ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... The opening is now the 19th sweetFrog store located in the Lone Star State. ... of fastest growing companies in 2014. , The store, which opened July 1 at ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... 20 Nordic Naturals was,recently named the ... of Vitamin and Supplement Users. Receiving two ... and #1 Rated Health Food,Store Brand for ... satisfaction ratings of all brands considered, throughout ...
... for cerebral aneurysms,with coil embolization (blocking of a ... another aneurysm, say neurological surgeons at Jefferson Hospital ... of its kind. , In a paper published ... Neurosurgery, researchers found there was an increased risk ...
... founder,and executive chairman of Aon Corporation, today announced he ... is the world,s largest,insurance and reinsurance intermediary, and a ... transition to a new management team under the,sound leadership ... continued growth and success. After 41 years as CEO ...
... Event is Open to the Public, Providing Access ... and Childhood,Illnesses, WASHINGTON, March 19 Mental ... area will have,an opportunity on Sunday, March 30th, ... in the military and about other serious mental ...
... number of terrestrial sources that yield novel treatments for ... been tapped as a promising resource for discovering new ... Diego, each utilizing mass spectrometry in novel ways, have ... from the sea that could one day treat diseases ...
... Corporation, a leading,international manufacturer, marketer, and supplier of ... its 2007 fourth,quarter and full year financial results., ... Company generated net sales of,$253.7 million, an increase ... in,the fourth quarter of 2006. Excluding the impact ...
Cached Medicine News:Health News:Nordic Naturals Named Top-Rated Supplement Brand in ConsumerLab.com Survey of Vitamin and Supplement Users! 2Health News:Smokers treated for brain aneurysm with coils at higher risk of recurrence 2Health News:Patrick G. Ryan Announces Intention to Retire from Aon 2Health News:Patrick G. Ryan Announces Intention to Retire from Aon 3Health News:NARSAD's 5th Annual 'Mission Possible' Symposium Offers Insight to PTSD and Other Mental Illnesses 2Health News:NARSAD's 5th Annual 'Mission Possible' Symposium Offers Insight to PTSD and Other Mental Illnesses 3Health News:NARSAD's 5th Annual 'Mission Possible' Symposium Offers Insight to PTSD and Other Mental Illnesses 4Health News:Researchers sharpen search for new marine medicines with novel techniques 2Health News:Researchers sharpen search for new marine medicines with novel techniques 3Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 2Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 3Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 4Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 5Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 6Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 7Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 8Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 9Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 10Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 11
... three-level control for monitoring and ... confirm cystic fibrosis. The controls ... Chloridometer, Flame Photometer, Osmometer, Sweat-Chek ... & Schales Titration, Synchron and ...
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... is intended as a means ... assay methods used for the ... urine samples. This control is ... This control is supplied as ...
Medicine Products: